CAR T https://www.bioworld.com/rss en-us Amen at AANEM: Kyverna makes good on MG phase II promise http://www.bioworld.com/articles/725591 Wed, 29 Oct 2025 11:00:00 -0400 https://www.bioworld.com/articles/725591-amen-at-aanem-kyverna-makes-good-on-mg-phase-ii-promise Illustration of nerve cells Immunoscape to develop new, safe TCR therapies for solid tumors http://www.bioworld.com/articles/706553 Tue, 12 Mar 2024 12:00:00 -0400 https://www.bioworld.com/articles/706553-immunoscape-to-develop-new-safe-tcr-therapies-for-solid-tumors 3D illustration of T cells fighting cancer Immunoscape to develop new, safe TCR therapies for solid tumors http://www.bioworld.com/articles/706402 Thu, 07 Mar 2024 12:00:00 -0500 https://www.bioworld.com/articles/706402-immunoscape-to-develop-new-safe-tcr-therapies-for-solid-tumors 3D illustration of T cells fighting cancer TYRP1 CAR T-cell therapy shows activity in models of melanoma http://www.bioworld.com/articles/705711 Thu, 22 Feb 2024 09:00:00 -0500 https://www.bioworld.com/articles/705711-tyrp1-car-t-cell-therapy-shows-activity-in-models-of-melanoma Co-culture that shows the CAR T-cell clusters attacking the tumor cells (in green) Co-culture that shows the CAR T-cell clusters attacking the tumor cells (in green). Credit: Puig-Saus laboratory Enhancing CAR T cells with degraders and ligases http://www.bioworld.com/articles/703374 Fri, 01 Dec 2023 09:00:00 -0500 https://www.bioworld.com/articles/703374-enhancing-car-t-cells-with-degraders-and-ligases CAR T cells attacking cancer cell Legend signs $1B T-cell therapy deal with Novartis http://www.bioworld.com/articles/702843 Tue, 14 Nov 2023 12:00:00 -0500 https://www.bioworld.com/articles/702843-legend-signs-1b-t-cell-therapy-deal-with-novartis CAR T cells attacking cancer cell Legend signs $1B T-cell therapy deal with Novartis http://www.bioworld.com/articles/702806 Mon, 13 Nov 2023 12:00:00 -0500 https://www.bioworld.com/articles/702806-legend-signs-1b-t-cell-therapy-deal-with-novartis CAR T cells attacking cancer cell Coimmune exercises option to target DLL3 with IL-18 armored CAR technology under MSK agreement http://www.bioworld.com/articles/698437 Wed, 28 Jun 2023 09:00:00 -0400 https://www.bioworld.com/articles/698437-coimmune-exercises-option-to-target-dll3-with-il-18-armored-car-technology-under-msk-agreement EHA 2023: IF they work, logic-gated CAR T cells could work BETTER for complex targeting http://www.bioworld.com/articles/697908 Tue, 13 Jun 2023 09:00:00 -0400 https://www.bioworld.com/articles/697908-eha-2023-if-they-work-logic-gated-car-t-cells-could-work-better-for-complex-targeting Genetically engineered β cells evade autoimmunity in type 1 diabetes model http://www.bioworld.com/articles/696195 Wed, 19 Apr 2023 09:00:00 -0400 https://www.bioworld.com/articles/696195-genetically-engineered-cells-evade-autoimmunity-in-type-1-diabetes-model Preclinically optimized CAR T-cell therapy targeting glypican-2 shows efficacy against neuroblastoma http://www.bioworld.com/articles/694435 Tue, 21 Feb 2023 09:00:00 -0500 https://www.bioworld.com/articles/694435-preclinically-optimized-car-t-cell-therapy-targeting-glypican-2-shows-efficacy-against-neuroblastoma Modulation of CAR T-cell activation increases therapy potency and persistency against ovarian cancer http://www.bioworld.com/articles/694433 Tue, 21 Feb 2023 09:00:00 -0500 https://www.bioworld.com/articles/694433-modulation-of-car-t-cell-activation-increases-therapy-potency-and-persistency-against-ovarian-cancer Ovarian cancer illustration CB-011, allogeneic BCMA-specific CAR-T cells engineered to prevent immune cell-mediated rejection http://www.bioworld.com/articles/694432 Tue, 21 Feb 2023 09:00:00 -0500 https://www.bioworld.com/articles/694432-cb-011-allogeneic-bcma-specific-car-t-cells-engineered-to-prevent-immune-cell-mediated-rejection Another Philadelphia story: Capstan premieres with $165M investment http://www.bioworld.com/articles/689656 Wed, 14 Sep 2022 12:00:00 -0400 https://www.bioworld.com/articles/689656-another-philadelphia-story-capstan-premieres-with-165m-investment CAR T cell with implanted gene strand Cellectis gears up for solid tumor research as ‘game-changing’ allogeneic CAR T cells edge toward market http://www.bioworld.com/articles/689494 Fri, 09 Sep 2022 12:00:00 -0400 https://www.bioworld.com/articles/689494-cellectis-gears-up-for-solid-tumor-research-as-game-changing-allogeneic-car-t-cells-edge-toward-market Microscope Celyad pauses phase Ib trial in colorectal cancer in latest CAR T solid tumor setback http://www.bioworld.com/articles/516487 Mon, 28 Feb 2022 12:00:00 -0500 https://www.bioworld.com/articles/516487-celyad-pauses-phase-ib-trial-in-colorectal-cancer-in-latest-car-t-solid-tumor-setback Cancer therapy pioneer calls CAR T ‘cure’ Nature Feb. 2.]]> http://www.bioworld.com/articles/515742 Thu, 03 Feb 2022 13:00:00 -0500 https://www.bioworld.com/articles/515742-cancer-therapy-pioneer-calls-car-t-cure Bill Ludwig and Carl June Carl June, right, pioneer of CAR T-cell therapy, with Bill Ludwig, the first patient treated with CAR T cells as part of clinical trials of the therapy at Penn’s Abramson Cancer Center. Credit: Penn Medicine Cancer therapy pioneer calls CAR T ‘cure’ Nature Feb. 2.]]> http://www.bioworld.com/articles/515720 Wed, 02 Feb 2022 12:00:00 -0500 https://www.bioworld.com/articles/515720-cancer-therapy-pioneer-calls-car-t-cure Bill Ludwig and Carl June Carl June, right, pioneer of CAR T-cell therapy, with Bill Ludwig, the first patient treated with CAR T cells as part of clinical trials of the therapy at Penn’s Abramson Cancer Center. Credit: Penn Medicine Thermo Fisher introduces modular, closed cell processing system http://www.bioworld.com/articles/499026 Thu, 15 Oct 2020 13:00:00 -0400 https://www.bioworld.com/articles/499026-thermo-fisher-introduces-modular-closed-cell-processing-system Rotea system next to tablet The Gibco CTS Rotea counterflow centrifugation system. Credit: Thermo Fisher Scientific Inc. Neogene’s $110M series A for individualized TCR approach in cancer http://www.bioworld.com/articles/497727 Mon, 14 Sep 2020 12:00:00 -0400 https://www.bioworld.com/articles/497727-neogenes-110m-series-a-for-individualized-tcr-approach-in-cancer Coins, stock chart illustration (Scorpion) Venom a-Blaze: arthritis, brain cancer superhero? http://www.bioworld.com/articles/433553 Fri, 06 Mar 2020 12:00:00 -0500 https://www.bioworld.com/articles/433553-scorpion-venom-a-blaze-arthritis-brain-cancer-superhero Scorpio maurus palmatus Scorpio maurus palmatus. Credit: Stuart Summerfield China approves two more CAR T trials; Legend’s candidate gets FDA breakthrough status http://www.bioworld.com/articles/432010 Tue, 24 Dec 2019 12:00:00 -0500 https://www.bioworld.com/articles/432010-china-approves-two-more-car-t-trials-legends-candidate-gets-fda-breakthrough-status Stem cells China approves two more CAR T trials; Legend’s candidate gets FDA breakthrough status http://www.bioworld.com/articles/431963 Fri, 20 Dec 2019 12:00:00 -0500 https://www.bioworld.com/articles/431963-china-approves-two-more-car-t-trials-legends-candidate-gets-fda-breakthrough-status Gene editing can move cell therapy from biplane to Boeing era http://www.bioworld.com/articles/431647 Mon, 09 Dec 2019 12:00:00 -0500 https://www.bioworld.com/articles/431647-gene-editing-can-move-cell-therapy-from-biplane-to-boeing-era CRISPR-Cas9 CRISPR-Cas9 is a customizable tool that allows editing of precise areas along a DNA strand. Credit: Ernesto del Aguila III, National Human Genome Research Institute, NIH Researchers develop CAR T cells tagged with bacterial enzyme that can be imaged http://www.bioworld.com/articles/431196 Tue, 19 Nov 2019 00:00:00 -0500 https://www.bioworld.com/articles/431196-upenn-researchers-develop-car-t-cells-tagged-with-bacterial-enzyme-that-can-be-imaged Hands holding petri dish Study shows CAR T cells can reverse cardiac fibrosis http://www.bioworld.com/articles/429363 Fri, 13 Sep 2019 00:00:00 -0400 https://www.bioworld.com/articles/429363-study-shows-car-t-cells-can-reverse-cardiac-fibrosis